Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Mar;93(3):501–508. doi: 10.1111/j.1476-5381.1988.tb10304.x

Celiprolol: a positive inotropic beta-adrenoceptor blocking agent in conscious dogs.

D M Nganele 1, V M DeLeonardis 1, T H Hintze 1
PMCID: PMC1853856  PMID: 2897217

Abstract

1. beta-Adrenoceptor blocking agents are used to manage various cardiovascular disorders. A limiting factor in their use is the suppression of the cardiac contractile state. In our study, we examined the cardiac effects of celiprolol, a new beta-adrenoceptor blocking agent with reported positive inotropic effects. 2. Dogs were instrumented by use of sterile surgical techniques for the study of myocardial inotropic state, heart rate and internal left ventricular dimensions. Following complete recovery from surgery, experiments were conducted in the conscious state. 3. Intravenous injection of celiprolol (3 mg kg-1) in nine dogs, increased LV dP/dt by 13 +/- 2.6%, velocity of shortening (LV dD/dt) by 9.2 +/- 3.4%, and heart rate by 19 +/- 4.6% and decreased LV end-diastolic diameter by 1.8 +/- 0.8%, all significantly (P less than 0.05). Celiprolol blocked the inotropic actions of isoprenaline (0.5 micrograms kg-1) but only partially reduced its hypotensive effects. Propranolol, in contrast, reduced LV dP/dt by 17 +/- 3.3% and heart rate by 8.1 +/- 2.7% (P less than 0.05) while totally abolishing the hypotension, tachycardia and increase in LV dP/dt caused by isoprenaline. Following beta-adrenoceptor blockade with propranolol and with heart rate held constant by electrical pacing, celiprolol increased LV dP/dt by 16 +/- 4.0%, LV dD/dt by 12 +/- 3.0% and reduced LV end-diastolic diameter by 3.5 +/- 0.5% (P less than 0.05). 4. Thus, in conscious dogs, celiprolol increases inotropic state and reduces preload independently of beta 1-adrenoceptor mechanisms and the Bowditch phenomenon, while effectively blocking beta 1-receptors in the heart. These properties would make celiprolol useful in patients where a conventional beta-adrenoceptor blocking agent might lead to pump failure.

Full text

PDF
501

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altura B. T., Altura B. M. Pentobarbital and contraction of vascular smooth muscle. Am J Physiol. 1975 Dec;229(6):1635–1640. doi: 10.1152/ajplegacy.1975.229.6.1635. [DOI] [PubMed] [Google Scholar]
  2. BING R. J. CARDIAC METABOLISM. Physiol Rev. 1965 Apr;45:171–213. doi: 10.1152/physrev.1965.45.2.171. [DOI] [PubMed] [Google Scholar]
  3. Chamberlain D. A. Effects of beta adrenergic blockade on heart size. Am J Cardiol. 1966 Sep;18(3):321–328. doi: 10.1016/0002-9149(66)90049-x. [DOI] [PubMed] [Google Scholar]
  4. Gerber J. G., Nies A. S. Beta-adrenergic blocking drugs. Annu Rev Med. 1985;36:145–164. doi: 10.1146/annurev.me.36.020185.001045. [DOI] [PubMed] [Google Scholar]
  5. Hintze T. H., Vatner S. F. Cardiac dynamics during hemorrhage. Relative unimportance of adrenergic inotropic responses. Circ Res. 1982 May;50(5):705–713. doi: 10.1161/01.res.50.5.705. [DOI] [PubMed] [Google Scholar]
  6. Holt G. W., Norris R. L., Ravenscroft P. J., Bett J. H., Dryburgh L. G., Boyle C. M. Effect of disopyramide on left ventricular performance: the relationship of free and total concentrations of the drug and of its mono-N-dealkylated metabolite to noninvasive indices of function. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):51–54. [PubMed] [Google Scholar]
  7. Holtz J., Saeed M., Sommer O., Bassenge E. Norepinephrine constricts the canine coronary bed via postsynaptic alpha 2-adrenoceptors. Eur J Pharmacol. 1982 Aug 27;82(3-4):199–202. doi: 10.1016/0014-2999(82)90513-1. [DOI] [PubMed] [Google Scholar]
  8. KOCH-WESER J., BLINKS J. R. THE INFLUENCE OF THE INTERVAL BETWEEN BEATS ON MYOCARDIAL CONTRACTILITY. Pharmacol Rev. 1963 Sep;15:601–652. [PubMed] [Google Scholar]
  9. Koch-Weser J., Frishman W. H. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981 Aug 27;305(9):500–506. doi: 10.1056/NEJM198108273050907. [DOI] [PubMed] [Google Scholar]
  10. Lewis C. M., Brink A. J. Beta adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease. Am J Cardiol. 1968 Jun;21(6):846–859. doi: 10.1016/0002-9149(68)90303-2. [DOI] [PubMed] [Google Scholar]
  11. Lucchesi B. R., Whitsitt L. S. The pharmacology of beta-adrenergic blocking agents. Prog Cardiovasc Dis. 1969 Mar;11(5):410–430. doi: 10.1016/0033-0620(69)90029-2. [DOI] [PubMed] [Google Scholar]
  12. Mahler F., Ross J., Jr, O'Rourke R. A., Covell J. W. Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phase measures of contractility in the conscious dog. Am J Cardiol. 1975 May;35(5):626–634. doi: 10.1016/0002-9149(75)90048-x. [DOI] [PubMed] [Google Scholar]
  13. Mahler F., Yoran C., Ross J., Jr Intropic effect of tachycardia and poststimulation potentiation in the conscious dog. Am J Physiol. 1974 Sep;227(3):569–575. doi: 10.1152/ajplegacy.1974.227.3.569. [DOI] [PubMed] [Google Scholar]
  14. Parker J. O., West R. O., Di Giorgi S. Hemodynamic effects of propranolol in coronary heart disease. Am J Cardiol. 1968 Jan;21(1):11–19. doi: 10.1016/0002-9149(68)90007-6. [DOI] [PubMed] [Google Scholar]
  15. Patrick T. A., Vatner S. F., Kemper W. S., Franklin D. Telemetry of left ventricular diameter and pressure measurements from unrestrained animals. J Appl Physiol. 1974 Aug;37(2):276–281. doi: 10.1152/jappl.1974.37.2.276. [DOI] [PubMed] [Google Scholar]
  16. Robertson R. M., Wood A. J., Vaughn W. K., Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation. 1982 Feb;65(2):281–285. doi: 10.1161/01.cir.65.2.281. [DOI] [PubMed] [Google Scholar]
  17. Vatner S. F., Braunwald E. Cardiovascular control mechanisms in the conscious state. N Engl J Med. 1975 Nov 6;293(19):970–976. doi: 10.1056/NEJM197511062931906. [DOI] [PubMed] [Google Scholar]
  18. Vatner S. F., Hintze T. H., Macho P. Regulation of large coronary arteries by beta-adrenergic mechanisms in the conscious dog. Circ Res. 1982 Jul;51(1):56–66. doi: 10.1161/01.res.51.1.56. [DOI] [PubMed] [Google Scholar]
  19. WALLACE A. G., SKINNER N. S., Jr, MITCHELL J. H. Hemodynamic determinants of the maximal rate of rise of left ventricular pressure. Am J Physiol. 1963 Jul;205:30–36. doi: 10.1152/ajplegacy.1963.205.1.30. [DOI] [PubMed] [Google Scholar]
  20. Wolf P. S., Smith R. D., Khandwala A., Van Inwegen R. G., Gordon R. J., Mann W. S., Romano D. V., Pruss T. P. Celiprolol--pharmacological profile of an unconventional beta-blocker. Br J Clin Pract Suppl. 1985 Jun;40:5–11. [PubMed] [Google Scholar]
  21. Wolfson S., Heinle R. A., Herman M. V., Kemp H. G., Sullivan J. M., Gorlin R. Propranolol and angina pectoris. Am J Cardiol. 1966 Sep;18(3):345–353. doi: 10.1016/0002-9149(66)90052-x. [DOI] [PubMed] [Google Scholar]
  22. van Herwaarden C. L. beta-Adrenoceptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease. J Cardiovasc Pharmacol. 1983;5 (Suppl 1):S46–S50. doi: 10.1097/00005344-198300051-00007. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES